TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q4 2025 Earnings Call Transcript March 5, 2026 TriSalus Life Sciences, Inc. beats earnings expectations. Reported EPS is $-0.12, expectations were $-0.13.
Resection of tumors in the caudate lobe (a deep, hard-to-reach part of the liver) is recognized as one of the most technically challenging procedures in hepatic surgery due to its unique anatomical ...
Resection of tumors in the caudate lobe (a deep, hard-to-reach part of the liver) is recognized as one of the most ...
When parts of the small intestine are diseased or die, the treatment can involve surgically removing the affected tissue.
Moby Strategic Execution and Platform Expansion. Revenue growth of 53% for the full year 2025 was driven by consistent ...
A 56-year-old man with liver failure has become the first living person to be surgically connected to a genetically modified ...
2d
TriSalus Life Sciences reaffirms $60M–$62M revenue guidance for 2026 while expanding PEDD portfolio
Q4 2025 earnings call recap: 60% revenue growth, 2026 guidance of $60–$62M, PEDD/TriNav expansion, funding and risks—read now.
Overview of secondary liver cancer care pathways, key treatment steps, and the situations where dendritic cell treatment may be discussed as a selected option.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results